Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Techne (TECH) Acquisitions (2016 - 2023)

Bio-Techne has reported Acquisitions over the past 10 years, most recently at $3.3 million for Q4 2023.

  • Quarterly results put Acquisitions at $3.3 million for Q4 2023, changed N/A from a year ago — trailing twelve months through Mar 2025 was $3.3 million (down 98.07% YoY), and the annual figure for FY2024 was $169.7 million, up 67.72%.
  • Acquisitions for Q4 2023 was $3.3 million at Bio-Techne, down from $166.4 million in the prior quarter.
  • Over the last five years, Acquisitions for TECH hit a ceiling of $166.4 million in Q3 2023 and a floor of -$1000.0 in Q1 2019.
  • Median Acquisitions over the past 4 years was $13.5 million (2019), compared with a mean of $49.6 million.
  • Peak annual rise in Acquisitions hit 517.81% in 2019, while the deepest fall reached 100.01% in 2019.
  • Bio-Techne's Acquisitions stood at $17.2 million in 2019, then tumbled by 43.25% to $9.8 million in 2021, then surged by 936.19% to $101.2 million in 2022, then tumbled by 96.76% to $3.3 million in 2023.
  • The last three reported values for Acquisitions were $3.3 million (Q4 2023), $166.4 million (Q3 2023), and $101.2 million (Q3 2022) per Business Quant data.